These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29977641)

  • 1. Evaluation of Tumor Viability for Primary and Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Using Whole-Body Magnetic Resonance Imaging.
    Iwamura H; Kaiho Y; Ito J; Anan G; Satani N; Matsuura T; Tamura R; Murakami K; Koyama K; Sato M
    Case Rep Urol; 2018; 2018():4074378. PubMed ID: 29977641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
    Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
    Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT.
    Kitajima K; Yamamoto S; Fujiwara M; Kawanaka Y; Yamada Y; Nagasawa S; Shimatani K; Hanasaki T; Taguchi M; Kanematsu A; Yamakado K
    Case Rep Oncol; 2021; 14(1):520-524. PubMed ID: 33976628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.
    Jacobs MA; Macura KJ; Zaheer A; Antonarakis ES; Stearns V; Wolff AC; Feiweier T; Kamel IR; Wahl RL; Pan L
    Acad Radiol; 2018 Nov; 25(11):1405-1414. PubMed ID: 29627288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
    Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
    Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
    Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
    Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of whole-body magnetic resonance diffusion weighted imaging on detection of malignant metastases.
    Li C; Liu ZS; Du XM; He L; Chen J; Wang W; Sun F; Du F; Luo ZG; Xue ZL; Zhao Y; Zhou CW
    Chin Med Sci J; 2009 Jun; 24(2):112-6. PubMed ID: 19618609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.
    Schmidt GP; Schoenberg SO; Schmid R; Stahl R; Tiling R; Becker CR; Reiser MF; Baur-Melnyk A
    Eur Radiol; 2007 Apr; 17(4):939-49. PubMed ID: 16951929
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
    Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
    Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Body MRI with Diffusion-Weighted Imaging in Bone Metastases: A Narrative Review.
    Stecco A; Trisoglio A; Soligo E; Berardo S; Sukhovei L; Carriero A
    Diagnostics (Basel); 2018 Jul; 8(3):. PubMed ID: 29987207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer.
    Kosmin M; Makris A; Joshi PV; Ah-See ML; Woolf D; Padhani AR
    Eur J Cancer; 2017 May; 77():109-116. PubMed ID: 28390297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging.
    Arita Y; Takahara T; Yoshida S; Kwee TC; Yajima S; Ishii C; Ishii R; Okuda S; Jinzaki M; Fujii Y
    Invest Radiol; 2019 Oct; 54(10):638-644. PubMed ID: 31192827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer.
    Eschmann SM; Pfannenberg AC; Rieger A; Aschoff P; Müller M; Paulsen F; Anastasiadis A; Claussen CD; Bares R; Schlemmer HP
    Nuklearmedizin; 2007; 46(5):161-8; quiz N47-8. PubMed ID: 17938748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.
    Pasoglou V; Michoux N; Van Damme J; Van Nieuwenhove S; Halut M; Triqueneaux P; Tombal B; Lecouvet FE
    World J Urol; 2019 Dec; 37(12):2585-2595. PubMed ID: 30826887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.